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Abstract
Prior studies have described distinct patterns of brain gray matter and white matter
alterations in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD),
as well as differences in their cerebrospinal fluid (CSF) biomarkers profiles. We aim to
investigate the relationship between early-onset AD (EOAD) and FTLD structural
alterations and CSF biomarker levels. We included 138 subjects (64 EOAD, 26 FTLD,
and 48 controls), all of them with a 3T MRI brain scan and CSF biomarkers available
(the 42 amino acid-long form of the amyloid-beta protein [Aβ42], total-tau protein [T-
tau], neurofilament light chain [NfL], neurogranin [Ng], and 14-3-3 levels). We used
FreeSurfer and FSL to obtain cortical thickness (CTh) and fraction anisotropy
(FA) maps. We studied group differences in CTh and FA and described the “AD signa-
ture” and “FTLD signature.” We tested multiple regression models to find which CSF-
biomarkers better explained each disease neuroimaging signature. CTh and FA maps
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corresponding to the AD and FTLD signatures were in accordance with previous
literature. Multiple regression analyses showed that the biomarkers that better
explained CTh values within the AD signature were Aβ and 14-3-3; whereas NfL and
14-3-3 levels explained CTh values within the FTLD signature. Similarly, NfL levels
explained FA values in the FTLD signature. Ng levels were not predictive in any of
the models. Biochemical markers contribute differently to structural (CTh and FA)
changes typical of AD and FTLD.
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1 | INTRODUCTION
Early-onset dementia (EOD) is usually defined by a clinical onset
under 65 and can reach up to the 5–10% of patients with dementia.
Alzheimer's disease (AD) is the most common cause of EOD, followed
by frontotemporal lobar degeneration (FTLD; Garre-Olmo, Genís
Batlle, del Mar Fernández, et al., 2010). Early-onset AD (EOAD) is
characterized by a faster disease progression and atypical presenta-
tions (nonamnestic symptoms) overlapping with other neurodegenera-
tive dementias such as FTLD making the diagnosis more challenging
(Koedam, Lauffer, van der Vlies, et al., 2010; Wattmo & Wallin, 2017).
Thus, the use of neuroimaging and biochemical biomarkers is espe-
cially suitable in EOD in order to establish an early and accurate diag-
nosis (Falgàs, Tort-Merino, Balasa, et al., 2019).
Several studies have aimed to determine the different profiles of
cerebrospinal fluid (CSF) biomarkers in different neurodegenerative
diseases such as AD or FTLD (Blennow & Zetterberg, 2018). Some of
these biomarker profiles have been well described while other novel
biomarkers are still under investigation. Decreased amyloid-beta pro-
tein 42 (Aβ42) with increased total tau (T-tau) and phosphorylated tau
(P-tau) levels define the typical AD biochemical profile (Albert,
DeKosky, Dickson, et al., 2011; Mattson, 2017; McKhann, Knopman,
Chertkow, et al., 2011) Regarding novel biomarkers, neurofilament
light chain (NfL) has been proposed as a nonspecific neu-
rodegeneration marker. Increased levels of NfL have been reported in
FTLD, as well as in AD and other neurodegenerative disorders
(i.e., amyotrophic lateral sclerosis or multiple sclerosis). CSF NfL levels
have proved especially useful differentiating FTLD from early-onset
AD given that NfL levels in AD are lower in early onset compared to
those in late onset presentations (Alcolea, Vilaplana, Suárez-Calvet,
et al., 2017; Olsson, Portelius, Cullen, et al., 2019; Portelius et al.,
2018; Sjögren, Rosengren, Minthon, et al., 2000). Neurogranin
(Ng) is a synaptic (dendritic) marker that has been suggested to be
specific for AD although increased levels are also found in
Creutzfeldt–Jakob diseases (Blennow, Diaz-Lucena, Zetterberg,
et al., 2019; Gaetani, Blennow, Calabresi, et al., 2019; Wellington
et al., 2016). The 14-3-3 protein has been extensively studied in
Creutzfeldt–Jakob disease, but its participation on the AD neuro-
pathological process has also been described (Burkhard, Sanchez,
Landis, et al., 2001; Chohan et al., 2010; McFerrin, Chi, Cutter,
et al., 2017). Furthermore, previous studies have suggested that
some of these biomarkers, as NfL or Ng, could provide information
about the disease prognosis in AD and FTLD, respectively (Ljubenkov
et al., 2018; Rohrer et al., 2016; Scherling et al., 2014).
Neuroimaging using Magnetic Resonance Imaging (MRI) has been
widely used to describe cortical thickness (CTh) and white matter
(WM) loss patterns in AD and FTLD as well as to find differential tra-
jectories along the different disease stages (Canu et al., 2017; Möller,
Hafkemeijer, Pijnenburg, et al., 2015; Moreno et al., 2013; Sala-Llonch
et al., 2015).
The relationship between AD neuroimaging features and classical
AD biochemical markers and their reciprocal influence have been
studied during both the clinical and preclinical phases of the disease
(Sala-Llonch et al., 2015). However, studying the influence of new bio-
markers is more challenging as the trajectories have been poorly
described and they might interact with those already reported, possi-
bly giving nontrivial relationships. In this sense, how the different CSF
biomarkers might explain or contribute to each disease atrophy pat-
tern is still uncertain (Idland et al., 2017; Pegueroles, 2017).
In this context, our goals were (a) to provide a descriptive anal-
ysis of CSF-biomarker levels and structural patterns (CTh, hippo-
campal volume, and FA) in early-onset AD and FTLD, (b) to study
the relationship between early-onset AD and FTLD brain structural
measures and CSF-biomarkers levels, and (c) to perform a multivari-
ate approach to evaluate which biomarkers better explained the
characteristic structural alterations associated with each disease
(i.e., disease signatures).
2 | MATERIALS AND METHODS
2.1 | Participants
One hundred thirty-eight subjects with disease onset under 65 were
evaluated at the Alzheimer's Disease and Other Cognitive Disorders
Unit at Hospital Clínic de Barcelona and were enrolled on this cross-
sectional study from 2009 to 2016. All subjects underwent a com-
plete neurological and neuropsychological evaluation, 3T brain MRI
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scan and a spinal tap for the determination of CSF biomarkers. Sub-
jects were classified into three groups:
• AD group (n = 64): All EOAD patients fulfilled the National Institute
on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria for MCI
due to AD or mild AD dementia and Mini-Mental State Examination
(MMSE) ≥18 (Albert et al., 2011; McKhann et al., 2011). All subjects
had a typical AD CSF biomarker pattern. Both early sporadic AD
(n = 52) and autosomal dominant AD (ADAD) (n = 12) were included.
• FTD group (n = 26): Ten behavioral variant of FTD (bvFTD) patients,
eight nonfluent variant for primary progressive aphasia (nfvPPA) and
eight semantic variant of primary progressive aphasia (svPPA)
patients were included Rascovsky et al., 2011; Gorno-Tempini et al.,
2011). Ten cases were genetic cases (four carried the C9ORF72
expansion, two MAPT mutations, and four GRN mutations). All FTLD
were at mild phases of the disease (MMSE ≥18) at inclusion.
• Healthy controls (CTR) (n = 48): healthy adults (age < 65 years old)
with no cognitive complaints, cognitive performance within norma-
tive range and normal levels of AD CSF biomarkers.
The study was approved by the Hospital Clinic Barcelona Ethics
Committee and all participants gave written informed consent.
2.2 | CSF biomarkers
• Commercially available single-analyte enzyme-linked immunosor-
bent assay (ELISA) kits were used to determine levels of CSF Aβ42,
T-tau and P-tau (INNOTEST, Fujirebio Europe N.V., Gent, Belgium),
NfL (IBL International, Hamburg, Germany) and 14-3-3 (CircuLex,
MBL International Corporation, Woburn, MA) at the Alzheimer's
Disease and Other Cognitive Disorders Unit Laboratory, Barcelona.
The following CSF cut-off values were used in order to classify the
subjects to NIA-A criteria as amyloid positive 550 pg/ml (CSF sam-
ples measured before February 2016) and 750 pg/ml (for those
measured after February 2016, due to changes in the commercial
kits), or neuronal injury positive (T-tau >385 pg/ml and/or P-tau
65 pg/ml). Cut-offs were obtained based on internal controls. CSF
Ng concentration was measured using an in-house ELISA based on
the monoclonal antibody Ng7 (epitope including amino acids 52–65
on Ng) at the Clinical Neurochemistry Laboratory, Sahlgrenska Uni-
versity Hospital, Mölndal, Sweden (Kvartsberg et al., 2015;
Willemse, De Vos, Herries, et al., 2018). The intracoefficient varia-
tion (CV) was 0.5–3% and the inter-CV 5–8% for NfL, Ng and
14-3-3 biomarkers. All 138 participants had CSF Aβ, T-tau, and P-
tau levels available. NfL levels were available in 133 subjects, Ng in
104, and 14-3-3 in 94.
2.3 | MRI acquisition
All participants were examined in the same 3T MRI scanner
(Magnetom Trio Tim, Siemens Medical Systems, Germany). A high-
resolution 3D structural data set (T1-weighted, MP-RAGE, repetition
time = 2,300 ms, echo time = 2.98 ms, 240 slices, field-of-
view = 256 mm, voxel size = 1 × 1 × 1 mm) and a diffusion weighted
echo-planar imaging (EPI) sequence (30 directions + b0 image, with
two repeated acquisitions, TR = 7,600 ms, TE = 89 ms, 60 slices, dis-
tance factor = 0%, FOV = 250 mm, matrix size =122 × 122, voxel
size = 2 × 2 × 2 mm) were acquired for all subjects.
2.4 | Statistical analysis of demographics and CSF-
biomarkers levels
We first obtained group descriptive data using the median and inter-
quantile range for each CSF biomarker within each group. Shapiro–
Wilk test for normality were done for each diagnostic group. Group
comparisons were analyzed using chi-square for gender or Kruskal–
Wallis tests for the rest of the variables. The significance threshold
was set at a Bonferroni corrected p level of .05 to adjust for multiple
comparisons (corrected p threshold = .0018).
Additionally, we performed additional analyses in order to com-
pare the subgroup of bvFTD subjects (N = 10) with the rest of the
FTLD patients. These were done also through Kruskall–Wallis tests.
2.5 | Cortical thickness processing and analysis
CTh processing and vertex-wise statistical analyses were performed
using FreeSurfer v6.0.0 (https://surfer.nmr.mgh.harvard.edu/). The
entire pipeline is fully explained elsewhere and includes a set of
methods applied to the T1-weighted MRI images to generate brain
surfaces and CTh maps, calculated as the closest distance between
the gray/WM surface to the pial surface at each vertex of the tessel-
lated surface (Dale, Fischl, & Sereno, 1999; Fischl & Dale, 2000).
Before statistics, individual CTh maps were registered to a common
space and smoothed using a FWHM of 15 mm.
Using the vertex-wise CTh data, we performed a set of analyses
using general linear models (GLMs). We first evaluated group differences,
using age as covariate. Then, for each biomarker, we computed the cor-
relation between the biomarker levels and CTh within each group.
Results were corrected for multiple comparisons using monte-carlo simu-
lations, and setting a threshold of p < .05 for cluster significance.
2.6 | Hippocampal volumes
Since the hippocampus is the main subcortical structure affected in
AD we also assessed the hippocampal volume. We used the auto-
mated segmentation from FreeSurfer to obtain measures of hippo-
campal volume (Fischl et al., 2002). We calculated normalized
hippocampal volume for each subject, by averaging left and right hip-
pocampi and dividing by the total intracranial volume. We then calcu-
lated group differences and correlations with biomarker levels in
hippocampal volume in R (https://www.r-project.org/.)
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2.7 | DTI processing and analysis
DTI processing and voxel-wise statistical analyses were performed with
FSL v5.0.11 (https://fsl.fmrib.ox.ac.uk/fsl). Diffusion weighted images
were first registered, using the B0 image as a reference volume, and
corrected for motion and for eddy current effects. Then, nonbrain tis-
sue was removed using FSL's Brain Extraction Tool, and FA maps were
obtained using the FMRIB Diffusion Toolbox. Tract-Based Spatial Sta-
tistics (TBSS) was used for voxel-wise statistical analysis of FA maps
(Smith, 2002; Smith et al., 2006). Basically, within the TBSS protocol,
nonlinear transforms were first applied using FNIRT to obtain FA
images aligned to standard space and the resulting images were merged
into single 4D image. Then, the mean of all FA images was fed into a
skeletonization protocol obtaining the group mean FA skeleton. Finally,
individual FA data were projected onto group skeleton.
DTI-based voxel-wise statistics on the FAmapswere carried out using
a permutation testing for nonparametric statistics using a GLM design. In a
first GLM, we included the three main groups (CTR, AD, and FTD), and we
tested for differences between the three groups using age as a covariate. In
a second set of analyses, we included individual biomarker values for each
group, and subjects' age. We tested for correlations between FA and each
biomarker in the three groups, using age as a covariate. This procedure was
performed separately forNFL, T-tau, Aβ, Ng, and 14-3-3.
2.8 | Disease-specific signatures and multiple
regression approaches
We created diseases signature maps, obtained from the group com-
parison analyses, namely CThAD and CThFTD and FAAD and FAFTD, for
the CTh and FA maps. In order to obtain descriptive overall patterns
of atrophy we first compared FTLD and AD groups separately against
the CTR. With the aim to explore differential alterations between
FTLD and AD, we created the neuroimaging signatures for each dis-
ease by directly comparing the two groups (i.e., AD < FTLD and the
FTLD<AD contrasts p < .05 corrected) for FA and CTh maps.
After creating these disease-specific signature maps, we obtained
individual CTh and FA values for each signature across the entire sam-
ple of subjects. We tested multiple regression models in order to evalu-
ate the predictive capabilities of the different biomarkers for each
signature, using Akaike Information Criterion (AIC) stepwise algorithm
in R (Sakamoto, Ishiguro, & Kitagawa, 1986). For that, we used a sample
of N = 75 subjects, corresponding to those that had complete sets of
MRI and CSF measures. Before multiple regression models, we evalu-
ated pair-wise correlations of the different CSF biomarkers. We then
created four separate models for predicting CThAD, CThFTD, FAAD, and
FAFTD, with Aβ, T-tau, NfL, Ng, 14-3-3 levels and age as predictors. We
used 90% confidence intervals obtained with bootstrapping algorithms
to study the significance of the models and the relative importance of
each predictor. In addition, we evaluated the multiple regression models
corresponding to the hippocampal volume and the MMSE results.
3 | RESULTS
3.1 | Sample demographics, clinical data, and
biomarkers
Demographic information, MMSE scores, and median levels of the
biomarkers are shown in Table 1. In summary, we found a slightly
TABLE 1 Demographics, clinical data, and CSF-biomarker values








Gender (m/f) 14/34 28/36 14/12 .11 .036 .38
AGE median [Q1, Q3] years 55.7 [49.5,61.1] 56.6 [54.5, 60.5] 60.6 [55.9, 64.7] .19 .0033 .019
Disease duration (years to LP) N/A 2.90 [1.61, 3.79] 2.88 [1.90, 3.78] N/A N/A 0.77
Aβ median [Q1, Q3] pg/ml 745.3 [618.6, 929.7] 392 [315.08, 454.6] 764.5 [626.9, 867.5] 1.1*10−14 .97 2.5*10−11
P-tau median [Q1, Q3] pg/ml 48.6 [38.8, 57.0] 105.6 [78.8, 140.6] 45.6 [36.7, 58.8] 3.6*10−15 .68 3.7*10−10
T-tau median [Q1, Q3] pg/ml 229.0 [165.5, 260.1] 690.8 [469.3, 1,033.0] 278.3 [211.5, 425.4] 1.4*10−18 .0013 8.4*10−9
NfL median [Q1, Q3] pg/ml 801.20 [517.2, 919.2] 1955.8 [1,602, 2,281] 4,682.5 [3,315, 6,048] 9.1*10−18 3.8*10−11 1.3*10−9
14-3-3 median [Q1, Q3] AU 2,532.6 [2,178, 2,734] 4,790.0 [3,708, 6,622] 3,942.5 [2,968, 4,783] 4.2*10−10 2.7*10−5 .013
Ng median [Q1, Q3] pg/ml 161.8 [125.6, 205.6] 246.3 [181.5, 306.8] 136.2 [92.1, 188.3] 4.2*10−6 .23 2.4*10−5
MMSE score median [Q1, Q3] 29.0 [29.0, 30.0] 23.0 [19.0, 26.5] 26.0 [24.0, 27.0] 1*10−13 5.1*10−5 .53
Note: Group summaries given as the median and the interquartile range of each measure. Pair-wise differences between groups are calculated using chi-
square for gender or Kruskal–Wallis tests for the rest of the variables. Significant group-differences are highlighted in bold (Bonferroni-corrected
p threshold = .0018).
Abbreviations: 14-3-3, 14-3-3 γ protein; Aβ, amyloid-beta protein 42; AD, Alzheimer's disease; AU, arbitrary units; CTR, controls; FTLD, frontotemporal
dementia; LP, lumbar puncture; MMSE, mini mental state examination; N/A, not-applicable; NfL, neurofilament light chain; Ng, neurogranine; P-tau,
phosphorylated-tau, T-tau, total-tau.
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greater proportion of females in the CTR group compared with the
FTLD group. FTLD subjects were slightly older than CTR and AD
groups (p < .05). MMSE scores were lower in both AD and FTLD
groups compared with CTR (p < .05), but did not differ between AD
and FTLD. We found lower Aβ42 and higher T-tau and P-tau concen-
trations in AD compared to FTLD and CTR. Compared to CTR, NfL,
and 14-3-3 were higher in both AD and FTD, but in AD and FTLD
comparison, NfL were higher in FTLD while 14-3-3 concentration was
higher in AD. Ng levels in AD were higher than in CTR and FTLD
(Table 1). Furthermore, we sub-analyzed the FTLD group compared to
the other types (Table S1).We found significant correlation between
several pairs of biomarkers, both in the whole sample or in the differ-
ent clinical groups (Tables S2–S5).
3.2 | CTh results
3.2.1 | Group differences in CTh
We found reduced CTh in frontal and temporal areas in FTLD com-
pared with CTR, and widespread CTh loss in AD (Figure 1). We use the
map resulting from the AD < FTLD contrast to represent the CThAD
signature, and the reverse contrast for the CThFTLD (see Figure 2a).
3.2.2 | Correlations between CTh and CSF
biomarkers
In FTLD, NfL levels showed a significant negative correlation with CTh in
a cluster located on the left hemisphere (cluster size = 15,667.98 mm2,
cluster p = .0001), covering mainly frontal areas, including the pars oper-
cularis, the pars triangularis, the middle and superior frontal, and the
precentral (Figure 3) gyrus. We also found a negative correlation
between CTh and T-tau levels across several bilateral frontal areas,
mainly the superior frontal gyrus (Figure 3). In AD, no correlations were
found between biomarker values and CTh.
3.3 | Hippocampal volumes
3.3.1 | Differences across diseases and
correlations with biomarkers
We found reduced normalized hippocampal volume in AD and in
FTLD compared with CTR (p = 7.5410−10 and p = 4.5110−09, respec-
tively). No differences in hippocampal volume were found between
AD and FTLD (p = .15).
When the three clinical groups were pulled together, normalized
hippocampal volume showed correlations with Aβ42 (p = .01, r = .22
age-corrected), T-tau (p = .046; r = −.17), NfL (p = .01, r = −.23), and
Ng (p = .046, r = −.20). We did not find any significant correlation
between normalized hippocampal volumes and CSF biomarkers, when
AD, FTLD, and CTR groups were studied separately (all p > .05).
3.4 | DTI results
3.4.1 | Group differences in FA
DTI analyses were performed with 112 subjects (49 AD, 23 FTLD,
and 40 CTR) with available DTI data of good quality. When comparing
FA maps across groups, we found patterns of significantly reduced FA
both for AD and FTLD versus CTR. These decreases were found gen-
erally across the entire skeleton for both diseases, with predominance
F IGURE 1 Group maps of
Alzheimer's disease and
frontotemporal lobar degeneration
patients compared with CTR.
(a) Voxel-wise maps of fraction
anisotropy differences, showing only
significant regions (corrected p < .05)
on the standard MNI template.
(b) Vertex-wise maps, showing
differences in cortical thickness
represented on the cortical surface
(corrected p < .05)
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in frontal areas and the left hemisphere in FTLD. When the two dis-
ease groups were compared, we found greater alterations in the left
hemisphere in FTLD, whereas we could not detect areas with lower
FA in AD. The signature pattern for FAFTLD was defined as the differ-
ence between the AD > FTLD (FAFTLD) maps, cut at p < .05 corrected
(Figure 2a). The FAAD signature could not be defined due to the lack
of significant differences in the AD > FTLD contrast.
3.4.2 | FA and CSF biomarkers correlation analysis
In AD patients, we found a significant negative correlation between
NfL values and FA in the forceps minor, the anterior thalamic radia-
tion, the cingulum, the corticospinal tract, the uncinate fasciculus, the
inferior longitudinal fasciculus, the inferior fronto-occipital fasciculus,
and the temporal part of the superior longitudinal fasciculus. In FTLD
patients, FA values in the forceps minor, the anterior thalamic radia-
tion, cingulum, forceps minor, and the left superior longitudinal fascic-
ulus correlated negatively with NfL (Figure 4). T-tau and 14-3-3
showed a negative correlation with FA in the forceps minor for the
FTLD group. The remaining biomarkers (Aβ, Ng) did not yield any sig-
nificant results.
3.4.3 | Disease signatures and multiple regression
results
The areas within each signature, representing different patterns of
structural damage in AD and FTLD, are described previously and
shown in Figure 2a.
In the multiple regression analysis, we found that Aβ42 and
14-3-3 levels contributed to predict CTh levels within the CThAD area,
explaining 28% of its variance, whereas CTh values within the
CThFTLD area was better predicted by NfL and 14-3-3, explaining 29%
of the variance. For FA values in FAFTLD, NfL was the main predictor,
explaining 56% of the variance. No regression analysis was performed
for FA values in AD because any regions survived the statistical
threshold in AD > FTLD contrast. Ng levels were not predictive in any
of the models (Table 2).
In addition to the disease signature patterns, we created models
for the hippocampus volumes (using the normalized bilateral volume)
and for the MMSE scores. We found that Aβ42, NfL, and AGE were
the factors that better explained the hippocampal volume (28% of var-
iance), whereas NfL, 14-3-3, and age, predicted the MMSE score
(28% variance) through the entire sample.
F IGURE 3 Vertex-wise maps of correlations between CTh and
cerebrospinal fluid-biomarkers in frontotemporal lobar degeneration
subjects
F IGURE 2 (a) Patterns of structural
alterations associated with Alzheimer's
disease and Frontotemporal Dementia
(frontotemporal lobar degeneration,
FTLD) (disease signatures). (b) Relative
importance (%) of each cerebrospinal fluid
biomarker and age in each multiple
regression model
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For each model, we calculated the relative importance of each
predictor and we found that NfL had the highest impact in CThFTLD
(89%) and it was the only variable depicted for FAFTLD, whereas Aβ
had the highest importance for CThAD (64%). The most important pre-
dictors for the hippocampal volume and for MMSE were NfL and
14-3-3, respectively (Figure 2b).
4 | DISCUSSION
We performed a cross-sectional study of structural GM and WM
alterations and their relationship with CSF biomarkers in early-onset
AD and FTLD. Differential patterns of brain loss and CSF biomarkers
profiles were found for both diseases. For the AD signatures, we
found that, in addition to Aβ, 14-3-3 was the only neurodegeneration
marker that significantly contributed to CTh levels variation, whereas
T-tau contributed to FA levels. For FTLD signatures, NfL and 14-3-3
were the main contributors to both CTh and FA values.
In our cohort, as expected, EOAD patients showed lower Aβ
and higher T-tau and P-tau CSF concentrations compared to FTLD
and controls (Mattson, 2017). NfL concentrations were higher in
both diseases compared with CTR, and in FTLD compared to AD, in
concordance with previous publications (Ljubenkov et al., 2018;
McFerrin et al., 2017; Sjögren et al., 2000). Ng in AD were higher
than controls and FTLD, but not significant differences were found
in FTLD with respect to CTR (Gaetani et al., 2019; Wellington et al.,
2016; Portelius et al., 2018; Lista, Toschi, Baldacci, et al., 2017).
There are few data about 14-3-3 levels in nonprion neurodegenera-
tive disorders, in our cohort, 14-3-3 levels were increased in AD
and FTLD compared with CTR and in AD compared with FTLD
(Burkhard et al., 2001).
We found cortical and subcortical (hippocampus) GM loss in both
AD and FTLD compared with controls. In general, the atrophy pattern
was more widespread in AD and presented a fronto-temporal pre-
dominance in FTLD in line with previous publications (Möller et al.,
2015; Rabinovici et al., 2007). We also found WM integrity loss in
both diseases, greater in FTLD than AD. These findings are similar to
previous studies evaluating the structural connectivity in neurodegen-
erative dementias that have suggested more WM damage in FTLD
compared to AD, especially in frontal and temporal regions (Canu
et al., 2017; Möller et al., 2015; Ossenkoppele et al., 2015; Zhang,
Schuff, Du, et al., 2009).
F IGURE 4 Voxel-wise maps of
correlation between fraction
anisotropy and cerebrospinal fluid-
biomarkers, studied separately for
each group
TABLE 2 Contribution of the different biomarkers and AGE to Alzheimer's disease and frontotemporal dementia imaging signatures and to
Hippocampal volume and MMSE scores
Aβ T-tau Nfl Ng 14-3-3 AGE R2
Variance explained
by model
CThAD 0.639 [0.19, 0.97] 0.361 [0.033, 0.807] 0.28 28%
FAAD N/A N/A N/A N/A N/A N/A N/A N/A
CThFTLD 0.890 [0.52, 0.99] 0.110 [0.001, 0.48] 0.31 29%
FAFTLD 1 0.56 56%
HV 0.365 [0.05, 0.69] 0.398 [0.039, 0.865] 0.237 [0.004, 0.64] 0.28 28%
MMSE 0.117 [0.0004, 0.58] 0.723 [0.22, 0.95] 0.160 [0.012, 0.41] 0.28 28%
Note: These data show results of a multiple regression models. Coefficients are normalized to show relative contribution of each variable.
Abbreviations: 14-3-3, 14-3-3 protein; Aβ, amyloid-beta protein 42; CThAD/CThFTLD, mean cortical thickness values within the AD/FTD signatures; FAAD/
FAFTD, mean FA values within the defined FA/AD signatures. HV, hippocampal volume; MMSE, mini mental state examination; N/A, not applicable; Nfl,
neurofilament light chain; Ng, neurogranine; P-tau, phosphorylated-tau, T-tau, total-tau.
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In the multivariate analysis, we found that AD and FTLD neuroim-
aging signatures were differentially influenced by CSF biomarkers. For
AD, Aβ was the biomarker that most contributed to CTh values in AD
signature. Unexpectedly 14-3-3 resulted a significant predictor of CTh
values while other neurodegeneration markers as T-tau, NfL, and
Ng did not. Previous studies have analyzed the contribution of Aβ
and T-tau to structural changes in AD (Blennow et al., 2019; Li
et al., 2014; Tosun, Schuff, Shaw, et al., 2011). The relevant con-
tribution of Aβ in the CTh AD signature in the present study is
plausible given its main role in AD pathophysiology. A plateau
effect of the Aβ load in symptomatic stages of the disease has
been defined, suggesting that brain atrophy might be more related
to tau spread rather than amyloid burden (Blennow & Zetterberg,
2018). In contrast, our results indicate that Aβ levels contribute to
the typical AD structural changes observed. Even if this effect
might be driven by the fact that low Aβ levels are a hallmark to all
the AD subjects included, we believe that it might also suggest an
effect in early symptomatic stages. However, we cannot claim that
the correlation found between Aβ and cortical brain atrophy in our
cohort demonstrates a causal relationship between them. Overall,
this finding highlights the complex relationships among different
biomarkers through the AD pathology. Moreover, in our cohort,
14-3-3 levels showed a strong correlation with T-tau levels both
in the whole group and in the different clinical subgroups. This
could suggest that the effect of T-tau observed in other studies
could be related to the 14-3-3 effect we observed in this study,
while here the strong correlation observed could cancel the effect
of T-tau in the regression model. Unfortunately, we could not
study the FAAD signature because we did not find any brain area
in which FA was significantly different in AD compared with
FTLD. This finding is in agreement with previously published data
and it could be attributed to a more intense WM damage in FTLD
(Möller et al., 2015).
Both CTh and FA values within the FTLD signature were mostly
explained by NfL levels, although 14-3-3 levels also contributed. NfL
values were associated CTh and FA values in the left frontal and tem-
poral regions in FTLD. These data support that NfL is a neu-
rodegeneration marker strongly related to FTLD (Ljubenkov et al.,
2018). These findings are also consistent with previous studies in
FTLD patients that reported correlations between brain structure and
NfL concentration especially in frontotemporal areas, with predomi-
nance in the left hemisphere (Rohrer et al., 2016; Scherling et al.,
2014). The relation of NfL with WM changes, beyond the GM loss, is
plausible as NfL is an axonal protein (Ossenkoppele et al., 2015).
Although we believe that studying the differences through the FTLD
spectrum could be of interest, in the present study, the sample was
not big enough to perform this approach for the different clinical vari-
ants separately.
14-3-3 was also the main factor in MMSE, supporting a role as a
nondisease specific marker of neurodegeneration. Regarding hippo-
campal volume, we found that Aβ and NfL accounted almost equally
models suggesting both CSF biomarkers could contribute to the sub-
cortical atrophy, as suggested previously (Idland et al., 2017).
Ng was the only CSF biomarker that did not influence any model,
despite being altered in AD subjects even if has been suggested to be
a specific biomarker of AD. Although our data further support previ-
ously reported elevated CSF Ng concentrations in AD compared with
FTLD and controls, it did not reach relevance enough to outstand in
the AD statistical model. These results are in line with a recent publi-
cation that reported that Ng did not show a diagnostic added value to
the classic basic AD biomarkers in terms of diagnostic accuracy (Lista
et al., 2017).
We should acknowledge several limitations in this study. First,
the relatively small sample size, especially in the FTLD group. In this
sense, the inclusion of different clinical FTLD variants can lead to
some variability within the FTLD group, but which in turn reflects the
heterogeneity of the FTLD itself. We also acknowledge that the fact
that the maps obtained from the groups are then used in the analysis
with biomarkers that also differ between groups could introduce some
circularity. However, we think that the goal of evaluating which bio-
markers better explained these structural changes is valid as we use
multiple regression models and the relevance of the result is the mag-
nitude of the effect of AD core biomarkers compared to other bio-
markers. Further studies in larger cohorts are needed to confirm and
expand these data.
In conclusion, our study suggests that biochemical markers might
contribute differently to structural (CTh and FA) changes typical of AD
and these results support the complexity of the relationship between
CSF biomarker and structural brain changes in these diseases.
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